🩸Facts about Multiple Myeloma:

Frontline Integration

#MultipleMyeloma #Hematology #BispecificAntibodies #StemCellTransplant #ASCT #BsAbs #MRD #ClinicalTrials #Elranatamab #Teclistamab #MajesTEC4 #MajesTEC5 #HemOnc #HEMEHUB

🩸 Additional insights on adverse events and management in Multiple Myeloma

#MultipleMyeloma #BCMA #GPRC5D #BispecificAntibodies #BsAbs #Immunotherapy #PlasmaCells #IVIG #Oncology #HemOnc #Hematology #ClinicalTrials #MajesTEC3 #HEMEHUB

🩸Facts about Multiple Myeloma:

Bispecific Antibodies (BsAbs) – Mechanism and Approval

#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd

NEW WORKSHOP "Top-Down, Intact, and Native Mass Spectrometry in Biopharmaceutical Characterization" Feb.12, 2026. Speakers from #AstraZeneca, #Novartis, #Pfizer, #Genentech, #Sanofi, #JnJ, #Lilly and #NIBRT share stories and perspectives. > ctdp.org/biopharma-wo... #ADCs #mAbs #BsAbs #TsAbs #AAVs

A recent study highlights bispecific antibodies #BsAbs as a powerful bridging therapy before BCMA CAR-T cell treatment for relapsed/refractory multiple myeloma #RRMM

@theaacr.bsky.social #bcd_aacr

#Onco404 #Cancer #Kanser #MultipleMyeloma #CARTCellTherapy #MedSky #Immunotherapy #Hematology